Boehringer Ingelheim Enters the Clinic with Two New Diabetes Drugs

Boehringer Ingelheim starts two new Phase I trials with drugs intended to treat type 2 diabetes and obesity discovered through a partnership with Danish biotech Zealand. 

The new Phase I trials initiated by Boehringer Ingelheim will be conducted in Germany, with results expected at the end of 2018. The drugs evaluated will be a long-acting amylin analog and a dual agonist of glucagon and GLP-1, both intended to improve the control of blood sugar levels in patients with type 2 diabetes and diabetes.

The drugs come from two ongoing research collaborations between Boehringer Ingelheim and the diabetes specialist Zealand Pharma, which will receive a €4M milestone payment following the start of clinical trials with the amylin analog. Together, both agreements sum €648M in outstanding milestone payments for the Danish biotech, plus royalties on future sales.

Zealand is experienced in the development of diabetes drugs for big pharma, including two GLP-1 drugs for Sanofi that are already in the market. For more info on new treatments for diabetes, including the popular GLP-1, read our review.


Image via Room’s Studio / Shutterstock

Previous post

Dutch Biotech could treat Dyslipidemia with Belgian Nanobody

Next post

Merck Ventures Joins Series A of Brisith Biotech Using Macrophages to Fight Cancer

Let's Continue The Conversation

Feel free to send us comments about this article to comments@labiotech.eu and/or comment on that article on social media.